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Abstract Using site-directed mutagenesis, changes of Tyr221 in
plasminogen activator inhibitor-1 (PAI-1) have provided mutants
with normal activity, but with increased stability. At physiolog-
ical conditions, the transition of the PAI-1 mutants Tyr221His
and Tyr221Ser to the latent form was significantly prolonged
(half-lives 14.8 and 4.1 h, respectively) as compared to wild-type
PAI-1 (2.0 h). Their half-lives, especially for the Tyr221Ser
mutant, were even more prolonged in the presence of vitronectin
(23.8 and 53.7 h, respectively). While wild-type PAI-1 was more
stable at lower pH, the PAI-1 mutants Tyr221His and Tyr221Ser
had stability optima at about pH 6.5, but displayed shorter half-
lives at pH 5.5.
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1. Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the physiolog-
ical inhibitor of tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA). Activation of
the ¢brinolytic system by plasminogen activators is important
for the physiological removal of ¢brin deposits in vivo, and
perhaps in preventing occlusive thrombotic disease [1].
PAI-1 is a glycoprotein, consisting of 379 amino acids [2,3].
It has a molecular weight of 50 000, while the recombinant
non-glycosylated PAI-1 expressed in prokaryotic cells has a
molecular weight of about 43 000. PAI-1 is a member of the
serpin superfamily of proteins [4]. Unlike most other serpins,
PAI-1 spontaneously converts to an inactive, ‘latent’, form
with a half-life of about 2 h at 37‡C and neutral pH [5,6].
Latent PAI-1 can be reactivated by protein denaturing agents,
such as guanidinium chloride or urea, followed by a slow
refolding, e.g. by dialysis against bu¡ers without denaturing
agents [7], preferably at a slightly decreased pH [8]. It is also
known that active PAI-1 is somewhat stabilized when associ-
ated with vitronectin [6]. The bait peptide bond, Arg346-
Met347, makes it possible for PAI-1 to form SDS-stable com-
plexes with tPA or uPA with a second-order rate constant of
about 2U107 mol31 l s31 [9].
Many studies about the function of the PAI-1 molecule
have been focussed on the vicinity of the bait peptide bond
[10^14], but other studies have shown that residues remote
from the reactive center loop of PAI-1 are also of importance
for the functional activity of PAI-1 [15,16].
In the present work, we have produced several mutations of
Tyr221 in PAI-1 and studied the e¡ects on di¡erent PAI-1
functions, including stability.
2. Materials and methods
2.1. Materials
Bacteria were cultured in BHI medium from Difco (USA). T4 DNA
ligase was purchased from Life Technologies AB (Taºby, Sweden). The
restriction enzymes EcoRI, HindIII, SacI, XhoI were from New Eng-
land Biolabs Inc. (Beverly, MA, USA). The expression vector,
pBV220, contains two heat-inducible promoters, VPR and VPL [17].
The full-length cDNA for PAI-1 was a kind gift of Prof. Paul De-
clerck, University of Leuven, Belgium. In PCR ampli¢cation, the
thermostable DNA polymerase, DyNAZyme, was from Finnzymes
Oy (Espoo, Finland). The deoxynucleoside phosphate set (A, C, G
and T) was purchased from Boehringer Mannheim AB (Bromma,
Sweden). QIAquick kit used in PCR product puri¢cation was from
Qiagen GmbH (Germany). Heparin-Sepharose CL-6B was purchased
from Pharmacia (Uppsala, Sweden). Acrylamide, N,NP-methylenebis-
acrylamide and anhydrotrypsin agarose were from Sigma-Aldrich
(Stockholm, Sweden). Kits for measuring PAI-1 antigen or activity
(Imulyse PAI-1 and Spectrolyze PL PAI-1 kits) were from Biopool
AB (Umeaî, Sweden). The monoclonal antibody towards PAI-1 (MAI-
12) was also obtained from Biopool. Synthetic oligonucleotides were
synthesized using a Gene Assembler Special system (Pharmacia). The
kit used in DNA sequencing was the Dye primer cycle sequencing,
Ready reaction-21M13, from Perkin-Elmer AB (Stockholm, Sweden).
Vitronectin was puri¢ed as described previously [18].
2.2. Expression procedure of rPAI-1 in Escherichia coli
The expression of rPAI-1 was carried out as described [19] with
some modi¢cations. The expression plasmid, pBV220/PAI-1, was
transformed to the E. coli host XL1 Blue. The bacteria were cultivated
in BHI medium containing 50 mg/l ampicillin at 30‡C overnight and it
was diluted by 1:50 into 1 l of the same medium. When the diluted
bacteria had grown at 30‡C for about 2.5 h (A650V0.5), the produc-
tion of rPAI-1 was initiated by increasing the temperature to 42‡C as
rapidly as possible. After 4 h cultivation at this temperature
(A650=1.5^1.6), the bacteria were harvested by centrifugation. The
pellet was quickly resuspended in 0.05 mol/l sodium acetate bu¡er,
pH 5.5, containing 0.1 mol/l sodium chloride, 0.1 g/l Tween 80 and 0.5
g/l glycerol. The bacteria were disrupted by addition of 200 Wg/ml
lysozyme, followed by incubation and 5U1 min sonication (at 90 W
and 0‡C) in the same bu¡er. After another centrifugation for 20 min
at 12 000Ug and 4‡C, the supernatant was subjected to the puri¢ca-
tion procedure as described below.
2.3. Puri¢cation of rPAI-1 by chromatographies
Puri¢cation of the PAI-1 variants was performed as described pre-
viously [20]. Brie£y, the supernatant was applied to a heparin-Sephar-
ose CL-6B column equilibrated with 0.05 mol/l sodium acetate bu¡er,
pH 5.5, containing 0.1 mol/l sodium chloride and 0.1 g/l Tween 80.
After washing, the rPAI-1 was eluted by a 200 ml gradient increasing
the sodium chloride concentration from 0.1 to 1.1 mol/l in the same
acetate bu¡er. The fractions containing highest PAI-1 antigen concen-
trations were pooled and subsequently subjected to chromatography
on anhydrotrypsin agarose.
The anhydrotrypsin agarose column (bed volume about 1.0 ml) was
equilibrated with 0.075 mol/l sodium phosphate bu¡er, pH 6.6, con-
taining 0.1 mol/l sodium chloride. About 0.1 mg of rPAI-1 was ap-
plied to the column and the unadsorbed protein, mostly latent PAI-1,
was washed out by the equilibration bu¡er. Then, elution was carried
out by 0.05 mol/l sodium acetate bu¡er, pH 5.5, containing 0.1 mol/l
sodium chloride and 0.1 g/l Tween 80. The eluted material was col-
lected and stored frozen at 370‡C.
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2.4. Mutagenesis of PAI-1 cDNA
The full-length PAI-1 cDNA with a XhoI site introduced at bp 871,
by synonymous mutation, encodes mature wild-type (wt) human PAI-
1. This PAI-1 cDNA was cloned between the EcoRI and HindIII sites
of pUC19. The generated plasmid, pUC19/PAI-1, was used as a tem-
plate in the following PCR ampli¢cations to introduce mutations in
PAI-1 cDNA.
The mutation primers (primers 1^5, Table 1) were used to produce
¢ve di¡erent PAI-1 mutants with Tyr221 substituted by di¡erent types
of amino acids: His, Ser, Phe, Lys and Asp. The primers were de-
signed to minimize the possibility of unwanted mutations caused by
an extra adenosine nucleotide added by DyNAZyme to the 3P-termi-
nus of DNA [21,22]. Also the conditions of PCR ampli¢cation were
optimized in order to reduce the risk of generating unwanted muta-
tions, by using minimal concentrations of deoxynucleotides and Dy-
NAZyme.
The procedure to introduce mutations at Tyr221 consisted of two-
step PCR ampli¢cations [20]. In the ¢rst PCR, the mutation primers
and primer 6 were used to get PCR products on pUC19/PAI-1. The
second step PCR employed the products of the ¢rst step PCR as
primers, together with primer 7, and PAI-1 cDNA as template. The
products in the second PCR were digested by SacI and XhoI and
subsequently used to replace the corresponding SacI-XhoI region in
the original PAI-1 cDNA. The sequence in the SacI-XhoI regions was
con¢rmed by DNA sequencing for all the PAI-1 mutants, while for
the mutants Tyr221Lys and Tyr221Asp the sequences were con¢rmed
for the whole coding region.
2.5. Determination of PAI-1 antigen and activity
PAI-1 antigen was measured by the Imulyse PAI-1 kit, using puri-
¢ed wtPAI-1 expressed in E. coli as a standard. The absorbance co-
e⁄cient of 7.7 for a 10 g/l wtPAI-1 solution was used [20]. PAI-1
activity was determined by inhibition of single-chain tPA, using the
Spectrolyze PL PAI-1 kit.
2.6. Interaction of PAI-1 with vitronectin
To quantify the interaction of PAI-1 variants with vitronectin, vi-
tronectin-coated microtiter plates were used, essentially as described
earlier [23]. Brie£y, PAI-1 variants, as well as reactivated native PAI-1
(from HT1080 cells), in di¡erent concentrations (¢nal concentrations
0^600 U/ml) were added to microtiter plates coated with vitronectin.
After incubation for 1 h at ambient temperature the plates were
washed and horseradish peroxidase-conjugated monoclonal antibodies
towards PAI-1 (MAI-12) were added. After incubation for another
hour, the plates were developed with o-phenylenediamine and H2O2.
The absorbance at 492 nm was recorded and used as a measure of the
PAI-1 binding to vitronectin.
2.7. Stability of PAI-1 mutants
The procedure was performed as previously described [20]. PAI-1
stability was studied as a function of pH (pH 5.5^8.5) at 37‡C and
temperature (0^37‡C) at pH 7.5. The bu¡ers used were 0.05 mol/l
sodium acetate bu¡er, pH 5.5; sodium phosphate bu¡er, pH 6.5 or
pH 7.5; or Tris-HCl bu¡er, pH 8.5. All bu¡ers also contained 0.1
mol/l sodium chloride, 0.5 mg/ml bovine serum albumin and 0.1 g/l
Tween 80. When needed, vitronectin was added to a ¢nal concentra-
tion of about 50 Wg/ml. The PAI-1 variants were diluted to ¢nal
concentrations of about 550 U/ml in the bu¡ers and incubated at
speci¢ed conditions. At various time intervals (0^144 h), 100 Wl sam-
ples were removed and slightly acidi¢ed with 8 Wl of 1 mol/l sodium
acetate bu¡er, pH 3.9, followed by addition of 25 Wl of PAI-1 depleted
plasma. The samples were then stored at 370‡C until analysis of PAI-
1 activity.
2.8. SDS-PAGE
SDS-PAGE was performed using a Mini-PROTEAN II Electro-
phoresis cell (Bio-Rad) according to the procedure described by
Laemmli [24]. 10% polyacrylamide gels were used and staining was
performed with Coomassie brilliant blue R-250.
3. Results
3.1. Expression, puri¢cation and activity of PAI-1 variants
The PAI-1 mutants Tyr221His, Tyr221Ser and Tyr221Phe, as
well as wtPAI-1, were found in a high yield, soluble in the
cytoplasm. In contrast, the PAI-1 mutants Tyr221Lys, and
Tyr221Asp repeatedly gave a very low yield in the supernatant
after bacterial lysis, but were rather found in insoluble inclu-
sion bodies. This suggested that these two mutants had much
lower solubility than the other PAI-1 variants, possibly due to
major conformational changes. Therefore, these two PAI-1
mutants were not further characterized in this paper.
The speci¢c activity data of the puri¢ed PAI-1 variants
were very similar and about 1U106 U/mg for all, utilizing
the standards included in the kits for PAI-1 activity and anti-
gen measurements. The speci¢c activity roughly doubled as a
result of puri¢cation on the anhydrotrypsin agarose column,
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Fig. 1. SDS-polyacrylamide gel electrophoresis of mixtures of the
PAI-1 variants and tPA. About 25 pmol of each PAI-1 variant was
mixed with about 45 pmol sctPA in a phosphate bu¡er of pH 7.3
(in a ¢nal volume of 100 Wl). After 20 min of incubation at ambient
temperature, 25 Wl of the mixture solution for each sample was ana-
lyzed by SDS-polyacrylamide gel electrophoresis which was per-
formed as described in methods. (A) means that the active PAI-1
variants which were eluted from the anhydrotrypsin agarose column
at pH 5.5, while (L) means that the latent PAI-1 variants which
went through the column at pH 6.6.
Table 1
Oligonucleotides for introducing mutations in PAI-1 cDNA and sequencing PAI-1 variants
No. Application Sequences of the oligonucleotides Position
1 Tyr221His GGCCATTACCACGACATCCTGG +655
2 Tyr221Phe GGCCATTACTTCGACATCCTGG +655
3 Tyr221Ser GGCCATTACTCCGACATCCTGG +655
4 Tyr221Lys GGCCATTACAAAGACATCCTGG +655
5 Tyr221Asp GGCCATTACGACGACATCCTGG +655
6 PCR CCCAGGTTCTCGAGGGGCTTCCTGAG 3884
7 PCR CAGCAGCAGATTCAAGCAG +166
Sequences are shown from 5P to 3P. The mutated nucleotides are printed in bold in all of the primers for introducing mutations. Location of each
5P nucleotide is given and the signs + and 3 indicate the coding and antisense strands, respectively.
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which mainly removes latent PAI-1 material. The similar spe-
ci¢c activities obtained for the di¡erent PAI-1 variants suggest
that the residue Tyr221 is of little importance for PAI-1 inhib-
itory function.
3.2. Formation of SDS-stable complexes between the PAI-1
variants and sctPA
When incubated with a slight excess of sctPA, virtually all
of the PAI-1 puri¢ed on the anhydrotrypsin agarose column
formed complexes with this enzyme (Fig. 1). Small amounts of
a cleaved form of PAI-1 were generated from all PAI-1 var-
iants during their reaction with sctPA, most likely due to the
presence of small amounts of the substrate form of the inhib-
itor [25,26]. The portion of the di¡erent PAI-1 variants that
were not adsorbed to the anhydrotrypsin agarose column also
did not react with sctPA (Fig. 1).
3.3. Stability of PAI-1 variants
The stability of the PAI-1 variants as a function of temper-
ature, in the absence or in the presence of vitronectin, is
shown in Table 2. As can be seen, all PAI-1 variants displayed
an increased stability at lower temperature. In the absence of
vitronectin at 22‡C, the half-lives of the PAI-1 variants were
about 6^10-fold prolonged as compared to at 37‡C. At 0‡C,
they were all almost completely stable (half-lives above 150 h).
The stability of the PAI-1 variants as a function of pH, in
the absence or in the presence of vitronectin, is shown in Fig.
2a,b, respectively. At pH 6.5 and above, the PAI-1 mutants
Tyr221His and Tyr221Ser were signi¢cantly more stable than
wtPAI-1, both in the absence and in the presence of vitronec-
tin. The half-lives of Tyr221His were up to 7 times prolonged,
both in the absence and in the presence of vitronectin. The
half-lives of Tyr221Ser were about doubled in the absence of
vitronectin and 10^16-fold increased in its presence. However,
at pH 5.5 in the absence of vitronectin, both these mutants
were less stable (2.5 h) as compared to wtPAI-1 (16.8 h). Both
in the absence and in the presence of vitronectin, wtPAI-1 was
more stable at lower pH than at higher pH, which is in agree-
ment with the behavior of ‘native’ PAI-1 in human plasma [6].
In contrast, however, the PAI-1 mutants Tyr221His and
Tyr221Ser were maximally stable at pH 6.5, but lost quite
dramatically in stability if pH was decreased to 5.5. In the
presence of vitronectin, at pH 5.5, these two mutants gained
considerably in stability, behaving almost as ‘native’ PAI-1.
The PAI-1 mutant Tyr221Phe had very similar stability prop-
erties to wtPAI-1 in the absence of vitronectin over the whole
pH range studied. In contrast to the result with the other
mutants, however, no e¡ect on the stability properties could
be found in the presence of vitronectin.
3.4. Binding of PAI-1 variants to vitronectin
The binding of PAI-1 mutants to vitronectin was studied
utilizing vitronectin-coated microtiter plates. Fig. 3 shows the
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Table 2
PAI-1 stability at pH 7.5 and 0, 22 or 37‡C in the absence or presence of vitronectin
In the absence of vitronectin In the presence of vitronectin
0‡C 22‡C 37‡C 0‡C 22‡C 37‡C
wtPAI-1 s 150 31.2 2 s 150 67.6 3
Tyr221His s 150 s 150 14.8 s 150 s 150 23.8
Tyr221Phe s 150 42.9 2.8 s 150 50.4 2.8
Tyr221Ser s 150 s 150 4.1 s 150 s 150 53.7
For experimental details see text. The ¢gures are given as half-lives (h).
Fig. 2. PAI-1 stability at 37‡C and di¡erent pH. a: In the absence
of vitronectin; b: in the presence of vitronectin. The PAI-1 variants
are indicated by: wtPAI-1 (b) ; Tyr221His (R) ; Tyr221Phe (F) and
Tyr221Ser (8).
Fig. 3. The binding of some of the PAI-1 variants to vitronectin-
coated microtiter plates as a function of PAI-1 activity concentra-
tion. The PAI-1 variants are shown by: wtPAI-1 (b) ; Tyr221His
(R) ; Tyr221Phe (F) and Tyr221Ser (8).
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binding curves of the di¡erent PAI-1 variants after puri¢ca-
tion on anhydrotrypsin agarose. Regarding the interaction
with vitronectin, wtPAI-1 protein expressed in E. coli had
an about 3-fold lower a⁄nity to vitronectin-coated microtiter
plates than reactivated PAI-1 obtained from HT1080 cells
(data not shown). All the PAI-1 mutants studied in this re-
port, Tyr221His, Tyr221Ser and Tyr221Phe, seem to bind to
vitronectin with a slightly decreased a⁄nity as compared to
wtPAI-1.
4. Discussion
The PAI-1 molecule, although synthesized as a fully active
molecule, is rapidly converted to an inactive ‘latent’ form of
the inhibitor at physiological conditions. For PAI-1 produced
by the ¢brosarcoma cell line HT1080 or native material in
plasma samples, the half-life for this transition is about 2 h
at neutral pH and 37‡C in the absence of vitronectin, but is
prolonged to about 4 h in the presence of vitronectin. The
mechanism for this transition is not fully understood, but
crystallographic data of the latent form [27] in connection
with structural data from other serpins have suggested that
insertion of the active site loop into the A L-pleated sheet
structure present in serpins plays an important role. In this
way the reactive center loop forms a new strand, between the
original strands 2 and 3 of this L-pleated sheet structure, ren-
dering the bait peptide bond in PAI-1 inaccessible to plasmi-
nogen activators. Recent data regarding the stabilization of
complexes between serine proteinases and serpins have em-
phasized the importance of partial reactive site loop insertion
as a result of the proteinase/serpin reaction [28^32].
In an elegant work by Berkenpas et al. [16], it was recently
demonstrated with the aid of random mutagenesis and selec-
tion of clones with increased stability, that exchange of a large
number of residues in di¡erent parts of the PAI-1 molecule
did indeed result in a stabler molecule. However, none of the
single-site changes caused any dramatic stabilization of the
molecule, but with several changes in combination they re-
ported a molecule with a half-life of about 150 h [16]. The
changes found to stabilize the PAI-1 molecule were almost
evenly distributed in the PAI-1 molecule, but with a tendency
of a cluster, in the reactive center loop. Interestingly, no mu-
tation was reported in strand 2 of the B L-sheet, but one was
found in strand 1 and three in strand 3. Tyrosine221, which is
found in strand 2 of this L-structure, upon mutation to a His
as reported in this paper, gives a molecule with a half-life of
about 15 h. Mutation of the same tyrosine residue to serine
gives a doubling of the stability in the absence of vitronectin.
However, for this mutant an almost 20-fold increased stability
is noted in the presence of vitronectin. The reason for the
increased stability has not been clari¢ed, but it is possible
that introduction of a positive charge or hydrophilic side
chain in this region, which is situated beneath the A L-struc-
ture, at about the point where insertion of the reactive center
loop starts, might result in an increased di⁄culty for a spon-
taneous reactive center loop insertion into the A L-sheet.
Whether the reason is a direct interaction with the reactive
site loop, an increased stability in the L-structure, or just a
steric hindrance for reactive peptide loop insertion is not
known at present, but must be a subject of future studies.
Nevertheless, since the activity of these mutants is not af-
fected, insertion of the reactive site loop following the inter-
action with plasminogen activators must still proceed in a
fairly normal way.
Another interesting observation is that the two mutants
Tyr221His and Tyr221Ser have maximal stability at about pH
6.5 and that they again become more labile at pH 5.5. These
data are in contrast to the results with wtPAI-1, native PAI-1
[6] and also regarding the PAI-1 mutant Tyr221Phe, which are
all more stable at pH 5.5 as compared to at higher pH. The
anomalous behavior is mostly found in the absence of vitro-
nectin. In the presence of vitronectin, all variants are very
stable at pH 5.5. Only the mutant Tyr221Ser is slightly more
active at pH 6.5 as compared to pH 5.5. Due to this anom-
alous pH dependence it can be speculated that a histidine
residue in the vicinity of Tyr221 might be of importance in
maintaining the conformation in this portion of the molecule
and that this plays a role for the active to latent PAI-1 tran-
sition. As seen in Fig. 2b, in the presence of vitronectin the
pH dependence is much less pronounced, suggesting that
changes induced in the PAI-1 mutants Tyr221His and
Tyr221Ser are, at least partially, counteracted by the interac-
tion with vitronectin.
It is also noted that the PAI-1 mutant Tyr221Phe does not
display an increased stability in the presence of vitronectin, in
contrast to all other mutants studied, even if its binding to
vitronectin is not dramatically altered. The reason for this is
not known, but it can be speculated that a conformational
change induced in PAI-1 by the interaction with vitronectin
is blocked if Tyr221 is mutated to a phenylalanine.
Thus, our data suggest that Tyr221 and perhaps an interac-
tion with a histidine residue in its vicinity is of importance for
the transition of functional PAI-1 to the latent form. At
present, work is being carried out to mutate the histidine
residues His185, His190, His219 and His229, which all are in
quite close vicinity to Tyr221, to ¢nd out if any one of these
is of importance for the pH-dependent stability of PAI-1.
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